Interferon-λ: Immune Functions at Barrier Surfaces and Beyond

Immunity

Volumn 43, Issue 1, 2015, Pages 15-28

  Lazear, HelenM ^a,b   Nice, TimothyJ ^a,c   Diamond, MichaelS ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CANCER GROWTH; CHRONIC DISEASE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TRACT; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; LIVER; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; RESPIRATORY SYSTEM; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS VIRULENCE; ANIMAL; BRAIN; IMMUNOLOGY; MOUSE; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIVIRAL AGENTS; AUTOIMMUNITY; BRAIN; GASTROINTESTINAL TRACT; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 84937722616     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.07.001     Document Type: Review

References (157)

1. Alexopoulou A., Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann. Gastroenterol. 2015, 28:55-65.
2. Angel J., Franco M.A., Greenberg H.B., Bass D. Lack of a role for type I and type II interferons in the resolution of rotavirus-induced diarrhea and infection in mice. J.Interferon Cytokine Res. 1999, 19:655-659.
3. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections invivo. J.Virol. 2006, 80:4501-4509.
4. Ank N., Iversen M.B., Bartholdy C., Staeheli P., Hartmann R., Jensen U.B., Dagnaes-Hansen F., Thomsen A.R., Chen Z., Haugen H., et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J.Immunol. 2008, 180:2474-2485.
5. Baker M.L., Schountz T., Wang L.F. Antiviral immune responses of bats: a review. Zoonoses Public Health 2013, 60:104-116.
6. Baldridge M.T., Nice T.J., McCune B.T., Yokoyama C.C., Kambal A., Wheadon M., Diamond M.S., Ivanova Y., Artyomov M., Virgin H.W. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science 2015, 347:266-269.
7. Bandi P., Pagliaccetti N.E., Robek M.D. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J.Interferon Cytokine Res. 2010, 30:123-134.
8. Baños-Lara Mdel.R., Harvey L., Mendoza A., Simms D., Chouljenko V.N., Wakamatsu N., Kousoulas K.G., Guerrero-Plata A. Impact and regulation of lambda interferon response in human metapneumovirus infection. J.Virol. 2015, 89:730-742.
9. Bibert S., Roger T., Calandra T., Bochud M., Cerny A., Semmo N., Duong F.H., Gerlach T., Malinverni R., Moradpour D., et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J.Exp. Med. 2013, 210:1109-1116. Swiss Hepatitis C Cohort Study.
10. Bibert S., Wojtowicz A., Taffé P., Manuel O., Bernasconi E., Furrer H., Günthard H.F., Hoffmann M., Kaiser L., Osthoff M., et al. The IFNL3/4 δG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 2014, 28:1885-1889. Swiss HIV Cohort Study.
11. Bierne H., Travier L., Mahlakõiv T., Tailleux L., Subtil A., Lebreton A., Paliwal A., Gicquel B., Staeheli P., Lecuit M., Cossart P. Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta. PLoS ONE 2012, 7:e39080.
12. Blazek K., Eames H.L., Weiss M., Byrne A.J., Perocheau D., Pease J.E., Doyle S., McCann F., Williams R.O., Udalova I.A. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J.Exp. Med. 2015, 212:845-853.
13. Bok K., Green K.Y. Norovirus gastroenteritis in immunocompromised patients. N.Engl. J. Med. 2012, 367:2126-2132.
14. Bolen C.R., Ding S., Robek M.D., Kleinstein S.H. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 2014, 59:1262-1272.
15. Booy S., Hofland L., van Eijck C. Potentials of interferon therapy in the treatment of pancreatic cancer. J.Interferon Cytokine Res. 2015, 35:327-339.
16. Burkart C., Arimoto K., Tang T., Cong X., Xiao N., Liu Y.C., Kotenko S.V., Ellies L.G., Zhang D.E. Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol. Med. 2013, 5:967-982.
17. Cannella F., Scagnolari C., Selvaggi C., Stentella P., Recine N., Antonelli G., Pierangeli A. Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med. Microbiol. Immunol. (Berl.) 2014, 203:177-184.
18. Christophers E., Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch. Dermatol. Res. 1987, 279(Suppl):S48-S51.
19. Clark R.A. Human skin in the game. Sci. Transl. Med. 2013, 5:204ps13.
20. Coccia E.M., Severa M., Giacomini E., Monneron D., Remoli M.E., Julkunen I., Cella M., Lande R., Uzé G. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 2004, 34:796-805.
21. Cohen T.S., Prince A.S. Bacterial pathogens activate a common inflammatory pathway through IFNλ regulation of PDCD4. PLoS Pathog. 2013, 9:e1003682.
22. Contoli M., Message S.D., Laza-Stanca V., Edwards M.R., Wark P.A., Bartlett N.W., Kebadze T., Mallia P., Stanciu L.A., Parker H.L., et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat. Med. 2006, 12:1023-1026.
23. Crotta S., Davidson S., Mahlakoiv T., Desmet C.J., Buckwalter M.R., Albert M.L., Staeheli P., Wack A. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog. 2013, 9:e1003773.
24. Crow Y.J. Type I interferonopathies: mendelian type I interferon up-regulation. Curr. Opin. Immunol. 2015, 32:7-12.
25. Dai J., Megjugorac N.J., Gallagher G.E., Yu R.Y., Gallagher G. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory Tcells. Blood 2009, 113:5829-5838.
26. Daniels B.P., Holman D.W., Cruz-Orengo L., Jujjavarapu H., Durrant D.M., Klein R.S. Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals. MBio 2014, 5. e01476-e14.
27. Dellgren C., Gad H.H., Hamming O.J., Melchjorsen J., Hartmann R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 2009, 10:125-131.
28. Dickensheets H., Sheikh F., Park O., Gao B., Donnelly R.P. Interferon-lambda (IFN-λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J.Leukoc. Biol. 2013, 93:377-385.
29. Di Trolio R., Simeone E., Di Lorenzo G., Buonerba C., Ascierto P.A. The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev. 2015, 26:203-212.
30. Donnelly R.P., Kotenko S.V. Interferon-lambda: a new addition to an old family. J.Interferon Cytokine Res. 2010, 30:555-564.
31. Donnelly R.P., Dickensheets H., O'Brien T.R. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 2011, 32:443-450.
32. Doyle S.E., Schreckhise H., Khuu-Duong K., Henderson K., Rosler R., Storey H., Yao L., Liu H., Barahmand-pour F., Sivakumar P., et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006, 44:896-906.
33. Dumoutier L., Tounsi A., Michiels T., Sommereyns C., Kotenko S.V., Renauld J.C. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J.Biol. Chem. 2004, 279:32269-32274.
34. Durbin R.K., Kotenko S.V., Durbin J.E. Interferon induction and function at the mucosal surface. Immunol. Rev. 2013, 255:25-39.
35. Egli A., Levin A., Santer D.M., Joyce M., O'Shea D., Thomas B.S., Lisboa L.F., Barakat K., Bhat R., Fischer K.P., et al. Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. J.Infect. Dis. 2014, 210:717-727.
36. Egli A., Santer D.M., O'Shea D., Barakat K., Syedbasha M., Vollmer M., Baluch A., Bhat R., Groenendyk J., Joyce M.A., et al. IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog. 2014, 10:e1004556.
37. Egli A., Santer D.M., O'Shea D., Tyrrell D.L., Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect 2014, 3:e51.
38. Epperson M.L., Lee C.A., Fremont D.H. Subversion of cytokine networks by virally encoded decoy receptors. Immunol. Rev. 2012, 250:199-215.
39. Eslam M., Hashem A.M., Leung R., Romero-Gomez M., Berg T., Dore G.J., Chan H.L., Irving W.L., Sheridan D., Abate M.L., et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat. Commun. 2015, 6:6422. International Hepatitis C Genetics Consortium (IHCGC).
40. Forrest J.C., Dermody T.S. Reovirus receptors and pathogenesis. J.Virol. 2003, 77:9109-9115.
41. Fox J.M., Crabtree J.M., Sage L.K., Tompkins S.M., Tripp R.A. Interferon Lambda Upregulates IDO1 Expression in Respiratory Epithelial Cells After Influenza Virus Infection. J.Interferon Cytokine Res. 2015, 10.1089/jir.2014.0052.
42. François-Newton V., Magno de Freitas Almeida G., Payelle-Brogard B., Monneron D., Pichard-Garcia L., Piehler J., Pellegrini S., Uzé G. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS ONE 2011, 6:e22200.
43. Gad H.H., Dellgren C., Hamming O.J., Vends S., Paludan S.R., Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J.Biol. Chem. 2009, 284:20869-20875.
44. Gallagher G., Megjugorac N.J., Yu R.Y., Eskdale J., Gallagher G.E., Siegel R., Tollar E. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J.Interferon Cytokine Res. 2010, 30:603-615.
45. Galmozzi E., Viganò M., Lampertico P. Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?. Aliment. Pharmacol. Ther. 2014, 39:569-578.
46. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
47. Génin P., Lin R., Hiscott J., Civas A. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 2009, 29:3435-3450.
48. Grayfer L., De Jesús Andino F., Robert J. Prominent amphibian (Xenopus laevis) tadpole type III interferon response to the frog virus 3 ranavirus. J.Virol. 2015, 89:5072-5082.
49. Griffiths S.J., Koegl M., Boutell C., Zenner H.L., Crump C.M., Pica F., Gonzalez O., Friedel C.C., Barry G., Martin K., et al. A systematic analysis of host factors reveals a Med23-interferon-λ regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog. 2013, 9:e1003514.
50. Griffiths S.J., Dunnigan C.M., Russell C.D., Haas J.G. The Role of Interferon-λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases. J.Innate Immun. 2015, 7:231-242.
51. Hamming O.J., Terczyńska-Dyla E., Vieyres G., Dijkman R., Jørgensen S.E., Akhtar H., Siupka P., Pietschmann T., Thiel V., Hartmann R. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 2013, 32:3055-3065.
52. Haralambieva I.H., Ovsyannikova I.G., Kennedy R.B., Vierkant R.A., Pankratz V.S., Jacobson R.M., Poland G.A. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 2011, 29:7883-7895.
53. Hayes C.N., Imamura M., Aikata H., Chayama K. Genetics of IL28B and HCV--response to infection and treatment. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:406-417.
54. Hermant P., Michiels T. Interferon-λ in the context of viral infections: production, response and therapeutic implications. J.Innate Immun. 2014, 6:563-574.
55. Hermant P., Demarez C., Mahlakõiv T., Staeheli P., Meuleman P., Michiels T. Human but not mouse hepatocytes respond to interferon-lambda invivo. PLoS ONE 2014, 9:e87906.
56. Hernández P.P., Mahlakõiv T., Yang I., Schwierzeck V., Nguyen N., Guendel F., Gronke K., Ryffel B., Hölscher C., Dumoutier L., et al. Interferon-λ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat. Immunol. 2015, 16:698-707.
57. Hillyer P., Mane V.P., Schramm L.M., Puig M., Verthelyi D., Chen A., Zhao Z., Navarro M.B., Kirschman K.D., Bykadi S., et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol. Cell Biol. 2012, 90:774-783.
58. Hoffmann H.H., Schneider W.M., Rice C.M. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 2015, 36:124-138.
59. Huang J., Smirnov S.V., Lewis-Antes A., Balan M., Li W., Tang S., Silke G.V., Pütz M.M., Smith G.L., Kotenko S.V. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc. Natl. Acad. Sci. USA 2007, 104:9822-9827.
60. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957, 147:258-267.
61. Iversen M.B., Paludan S.R. Mechanisms of type III interferon expression. J.Interferon Cytokine Res. 2010, 30:573-578.
62. Iversen M.B., Ank N., Melchjorsen J., Paludan S.R. Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J.Virol. 2010, 84:4579-4586.
63. Jewell N.A., Cline T., Mertz S.E., Smirnov S.V., Flaño E., Schindler C., Grieves J.L., Durbin R.K., Kotenko S.V., Durbin J.E. Lambda interferon is the predominant interferon induced by influenza A virus infection invivo. J.Virol. 2010, 84:11515-11522.
64. Jones M.K., Watanabe M., Zhu S., Graves C.L., Keyes L.R., Grau K.R., Gonzalez-Hernandez M.B., Iovine N.M., Wobus C.E., Vinjé J., et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 2014, 346:755-759.
65. Jordan W.J., Eskdale J., Boniotto M., Rodia M., Kellner D., Gallagher G. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 2007, 8:13-20.
66. Jordan W.J., Eskdale J., Srinivas S., Pekarek V., Kelner D., Rodia M., Gallagher G. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 2007, 8:254-261.
67. Kane M., Case L.K., Kopaskie K., Kozlova A., MacDearmid C., Chervonsky A.V., Golovkina T.V. Successful transmission of a retrovirus depends on the commensal microbiota. Science 2011, 334:245-249.
68. Karst S.M., Wobus C.E., Goodfellow I.G., Green K.Y., Virgin H.W. Advances in norovirus biology. Cell Host Microbe 2014, 15:668-680.
69. Key F.M., Peter B., Dennis M.Y., Huerta-Sánchez E., Tang W., Prokunina-Olsson L., Nielsen R., Andrés A.M. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet. 2014, 10:e1004681.
70. Kim H.J., Kim C.H., Ryu J.H., Kim M.J., Park C.Y., Lee J.M., Holtzman M.J., Yoon J.H. Reactive oxygen species induce antiviral innate immune response through IFN-λ regulation in human nasal epithelial cells. Am. J. Respir. Cell Mol. Biol. 2013, 49:855-865.
71. Koch S., Finotto S. Role of Interferon-λ in Allergic Asthma. J.Innate Immun. 2015, 7:224-230.
72. Kohli A., Zhang X., Yang J., Russell R.S., Donnelly R.P., Sheikh F., Sherman A., Young H., Imamichi T., Lempicki R.A., et al. Distinct and overlapping genomic profiles and antiviral effects of Interferon-λ and -α on HCV-infected and noninfected hepatoma cells. J.Viral Hepat. 2012, 19:843-853.
73. Koltsida O., Hausding M., Stavropoulos A., Koch S., Tzelepis G., Ubel C., Kotenko S.V., Sideras P., Lehr H.A., Tepe M., et al. IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol. Med. 2011, 3:348-361.
74. Kotenko S.V. IFN-λs. Curr. Opin. Immunol. 2011, 23:583-590.
75. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., Donnelly R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4:69-77.
76. Koyuncu O.O., Hogue I.B., Enquist L.W. Virus infections in the nervous system. Cell Host Microbe 2013, 13:379-393.
77. Kuss S.K., Best G.T., Etheredge C.A., Pruijssers A.J., Frierson J.M., Hooper L.V., Dermody T.S., Pfeiffer J.K. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 2011, 334:249-252.
78. Lampertico P., Viganò M., Cheroni C., Facchetti F., Invernizzi F., Valveri V., Soffredini R., Abrignani S., De Francesco R., Colombo M. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013, 57:890-896.
79. Lasfar A., Lewis-Antes A., Smirnov S.V., Anantha S., Abushahba W., Tian B., Reuhl K., Dickensheets H., Sheikh F., Donnelly R.P., et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res. 2006, 66:4468-4477.
80. Lauterbach H., Bathke B., Gilles S., Traidl-Hoffmann C., Luber C.A., Fejer G., Freudenberg M.A., Davey G.M., Vremec D., Kallies A., et al. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J.Exp. Med. 2010, 207:2703-2717.
81. Lazear H.M., Daniels B.P., Pinto A.K., Huang A.C., Vick S.C., Doyle S.E., Gale M., Klein R.S., Diamond M.S. Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci. Transl. Med. 2015, 7:284ra59.
82. Lebreton A., Lakisic G., Job V., Fritsch L., Tham T.N., Camejo A., Matteï P.J., Regnault B., Nahori M.A., Cabanes D., et al. A bacterial protein targets the BAHD1 chromatin complex to stimulate type III interferon response. Science 2011, 331:1319-1321.
83. Leung D.Y. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol. Int. 2013, 62:151-161.
84. Li W., Lewis-Antes A., Huang J., Balan M., Kotenko S.V. Regulation of apoptosis by type III interferons. Cell Prolif. 2008, 41:960-979.
85. Li Y., Cheng H., Zuo X.B., Sheng Y.J., Zhou F.S., Tang X.F., Tang H.Y., Gao J.P., Zhang Z., He S.M., et al. Association analyses identifying two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in the Chinese Han population. J.Med. Genet. 2013, 50:812-818.
86. Lopez S., Arias C.F. Early steps in rotavirus cell entry. Curr. Top. Microbiol. Immunol. 2006, 309:39-66.
87. Lopez de Lapuente A., Alloza I., Goertsches R., Zettl U.K., Urcelay E., Arroyo R., Comabella M., Montalban X., Antigüedad A., Vandenbroeck K. Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. J.Neuroimmunol. 2012, 245:98-101.
88. Love A.C., Schwartz I., Petzke M.M. Borrelia burgdorferi RNA induces type I and III interferons via Toll-like receptor 7 and contributes to production of NF-κB-dependent cytokines. Infect. Immun. 2014, 82:2405-2416.
89. Ma D., Jiang D., Qing M., Weidner J.M., Qu X., Guo H., Chang J., Gu B., Shi P.Y., Block T.M., Guo J.T. Antiviral effect of interferon lambda against West Nile virus. Antiviral Res. 2009, 83:53-60.
90. Mahlakõiv T., Ritz D., Mordstein M., DeDiego M.L., Enjuanes L., Müller M.A., Drosten C., Staeheli P. Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread. J.Gen. Virol. 2012, 93:2601-2605.
91. Mahlakõiv T., Hernandez P., Gronke K., Diefenbach A., Staeheli P. Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 2015, 11:e1004782.
92. Malhotra S., Morcillo-Suárez C., Brassat D., Goertsches R., Lechner-Scott J., Urcelay E., Fernández O., Drulovic J., García-Merino A., Martinelli Boneschi F., et al. IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis. J.Neuroimmunol. 2011, 239:101-104.
93. Manuel O., Wójtowicz A., Bibert S., Mueller N.J., van Delden C., Hirsch H.H., Steiger J., Stern M., Egli A., Garzoni C., et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J.Infect. Dis. 2015, 211:906-914. Swiss Transplant Cohort Study.
94. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R., Rice C.M. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-1898.
95. Markowitz C.E. Interferon-beta: mechanism of action and dosing issues. Neurology 2007, 68(24, Suppl 4):S8-S11.
96. Marukian S., Andrus L., Sheahan T.P., Jones C.T., Charles E.D., Ploss A., Rice C.M., Dustin L.B. Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology 2011, 54:1913-1923.
97. McFarland A.P., Horner S.M., Jarret A., Joslyn R.C., Bindewald E., Shapiro B.A., Delker D.A., Hagedorn C.H., Carrington M., Gale M., Savan R. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat. Immunol. 2014, 15:72-79.
98. Miknis Z.J., Magracheva E., Li W., Zdanov A., Kotenko S.V., Wlodawer A. Crystal structure of human interferon-λ1 in complex with its high-affinity receptor interferon-λR1. J.Mol. Biol. 2010, 404:650-664.
99. Misumi I., Whitmire J.K. IFN-λ exerts opposing effects on Tcell responses depending on the chronicity of the virus infection. J.Immunol. 2014, 192:3596-3606.
100. Mordstein M., Kochs G., Dumoutier L., Renauld J.C., Paludan S.R., Klucher K., Staeheli P. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008, 4:e1000151.
101. Mordstein M., Michiels T., Staeheli P. What have we learned from the IL28 receptor knockout mouse?. J.Interferon Cytokine Res. 2010, 30:579-584.
102. Mordstein M., Neugebauer E., Ditt V., Jessen B., Rieger T., Falcone V., Sorgeloos F., Ehl S., Mayer D., Kochs G., et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J.Virol. 2010, 84:5670-5677.
103. Morrow M.P., Pankhong P., Laddy D.J., Schoenly K.A., Yan J., Cisper N., Weiner D.B. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009, 113:5868-5877.
104. Muir A.J., Arora S., Everson G., Flisiak R., George J., Ghalib R., Gordon S.C., Gray T., Greenbloom S., Hassanein T., et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J.Hepatol. 2014, 61:1238-1246. EMERGE study group.
105. Nice T.J., Strong D.W., McCune B.T., Pohl C.S., Virgin H.W. A single-amino-acid change in murine norovirus NS1/2 is sufficient for colonic tropism and persistence. J.Virol. 2013, 87:327-334.
106. Nice T.J., Baldridge M.T., McCune B.T., Norman J.M., Lazear H.M., Artyomov M., Diamond M.S., Virgin H.W. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science 2015, 347:269-273.
107. Numasaki M., Tagawa M., Iwata F., Suzuki T., Nakamura A., Okada M., Iwakura Y., Aiba S., Yamaya M. IL-28 elicits antitumor responses against murine fibrosarcoma. J.Immunol. 2007, 178:5086-5098.
108. O'Brien T.R., Prokunina-Olsson L., Donnelly R.P. IFN-λ4: the paradoxical new member of the interferon lambda family. J.Interferon Cytokine Res. 2014, 34:829-838.
109. Odendall C., Kagan J.C. The unique regulation and functions of type III interferons in antiviral immunity. Curr. Opin. Virol. 2015, 12:47-52.
110. Odendall C., Dixit E., Stavru F., Bierne H., Franz K.M., Durbin A.F., Boulant S., Gehrke L., Cossart P., Kagan J.C. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat. Immunol. 2014, 15:717-726.
111. Okabayashi T., Kojima T., Masaki T., Yokota S., Imaizumi T., Tsutsumi H., Himi T., Fujii N., Sawada N. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 2011, 160:360-366.
112. Onoguchi K., Yoneyama M., Takemura A., Akira S., Taniguchi T., Namiki H., Fujita T. Viral infections activate types I and III interferon genes through a common mechanism. J.Biol. Chem. 2007, 282:7576-7581.
113. Osterlund P.I., Pietilä T.E., Veckman V., Kotenko S.V., Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J.Immunol. 2007, 179:3434-3442.
114. Pagliaccetti N.E., Robek M.D. Interferon-λ in HCV Infection and Therapy. Viruses 2010, 2:1589-1602.
115. Park H., Serti E., Eke O., Muchmore B., Prokunina-Olsson L., Capone S., Folgori A., Rehermann B. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012, 56:2060-2070.
116. Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu. Rev. Pathol. 2012, 7:385-422.
117. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J.Biol. Chem. 2007, 282:20047-20051.
118. Pietilä T.E., Latvala S., Osterlund P., Julkunen I. Inhibition of dynamin-dependent endocytosis interferes with type III IFN expression in bacteria-infected human monocyte-derived DCs. J.Leukoc. Biol. 2010, 88:665-674.
119. Pott J., Mahlakõiv T., Mordstein M., Duerr C.U., Michiels T., Stockinger S., Staeheli P., Hornef M.W. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. USA 2011, 108:7944-7949.
120. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., Hergott D., Porter-Gill P., Mumy A., Kohaar I., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013, 45:164-171.
121. Qi Z., Nie P., Secombes C.J., Zou J. Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs. J.Immunol. 2010, 184:5038-5046.
122. Reuter A., Soubies S., Härtle S., Schusser B., Kaspers B., Staeheli P., Rubbenstroth D. Antiviral activity of lambda interferon in chickens. J.Virol. 2014, 88:2835-2843.
123. Rigby R.E., Rehwinkel J. RNA degradation in antiviral immunity and autoimmunity. Trends Immunol. 2015, 36:179-188.
124. Russell C.D., Griffiths S.J., Haas J. Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg?. DNA Cell Biol. 2014, 33:60-63.
125. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010, 21:315-324.
126. Sato A., Ohtsuki M., Hata M., Kobayashi E., Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J.Immunol. 2006, 176:7686-7694.
127. Sato S., Li K., Kameyama T., Hayashi T., Ishida Y., Murakami S., Watanabe T., Iijima S., Sakurai Y., Watashi K., et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 2015, 42:123-132.
128. Sheahan T., Imanaka N., Marukian S., Dorner M., Liu P., Ploss A., Rice C.M. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 2014, 15:190-202.
129. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63-68.
130. Shindo H., Maekawa S., Komase K., Miura M., Kadokura M., Sueki R., Komatsu N., Shindo K., Amemiya F., Nakayama Y., et al. IL-28B (IFN-λ3) and IFN-α synergistically inhibit HCV replication. J.Viral Hepat. 2013, 20:281-289.
131. Siegel R., Eskdale J., Gallagher G. Regulation of IFN-λ1 promoter activity (IFN-λ1/IL-29) in human airway epithelial cells. J.Immunol. 2011, 187:5636-5644.
132. Sommereyns C., Paul S., Staeheli P., Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells invivo. PLoS Pathog. 2008, 4:e1000017.
133. Sorgeloos F., Kreit M., Hermant P., Lardinois C., Michiels T. Antiviral type I and type III interferon responses in the central nervous system. Viruses 2013, 5:834-857.
134. Souza-Fonseca-Guimaraes F., Young A., Mittal D., Martinet L., Bruedigam C., Takeda K., Andoniou C.E., Degli-Esposti M.A., Hill G.R., Smyth M.J. NK cells require IL-28R for optimal invivo activity. Proc. Natl. Acad. Sci. USA 2015, 112:E2376-E2384.
135. Srinivas S., Dai J., Eskdale J., Gallagher G.E., Megjugorac N.J., Gallagher G. Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses invitro. Immunology 2008, 125:492-502.
136. Stifter S.A., Feng C.G. Interfering with immunity: detrimental role of type I IFNs during infection. J.Immunol. 2015, 194:2455-2465.
137. Strange A., Capon F., Spencer C.C., Knight J., Weale M.E., Allen M.H., Barton A., Band G., Bellenguez C., Bergboer J.G., et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 2010, 42:985-990. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2.
138. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
139. Swider A., Siegel R., Eskdale J., Gallagher G. Regulation of interferon lambda-1 (IFNL1/IFN-λ1/IL-29) expression in human colon epithelial cells. Cytokine 2014, 65:17-23.
140. Swiecki M., Colonna M. Type I interferons: diversity of sources, production pathways and effects on immune responses. Curr. Opin. Virol. 2011, 1:463-475.
141. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
142. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
143. Thomas E., Gonzalez V.D., Li Q., Modi A.A., Chen W., Noureddin M., Rotman Y., Liang T.J. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012, 142:978-988.
144. Thomson S.J., Goh F.G., Banks H., Krausgruber T., Kotenko S.V., Foxwell B.M., Udalova I.A. The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc. Natl. Acad. Sci. USA 2009, 106:11564-11569.
145. Travar M., Vucic M., Petkovic M. Interferon lambda-2 levels in sputum of patients with pulmonary Mycobacterium tuberculosis infection. Scand. J. Immunol. 2014, 80:43-49.
146. Urban T.J., Thompson A.J., Bradrick S.S., Fellay J., Schuppan D., Cronin K.D., Hong L., McKenzie A., Patel K., Shianna K.V., et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52:1888-1896.
147. Witte K., Gruetz G., Volk H.D., Looman A.C., Asadullah K., Sterry W., Sabat R., Wolk K. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009, 10:702-714.
148. Wobus C.E., Karst S.M., Thackray L.B., Chang K.O., Sosnovtsev S.V., Belliot G., Krug A., Mackenzie J.M., Green K.Y., Virgin H.W. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2004, 2:e432.
149. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
150. Wolk K., Witte K., Witte E., Raftery M., Kokolakis G., Philipp S., Schönrich G., Warszawska K., Kirsch S., Prösch S., et al. IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci. Transl. Med. 2013, 5:204ra129.
151. Wollenberg A., Wetzel S., Burgdorf W.H., Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J.Allergy Clin. Immunol. 2003, 112:667-674.
152. Wongthida P., Diaz R.M., Galivo F., Kottke T., Thompson J., Pulido J., Pavelko K., Pease L., Melcher A., Vile R. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res. 2010, 70:4539-4549.
153. Zhang X., Brann T.W., Zhou M., Yang J., Oguariri R.M., Lidie K.B., Imamichi H., Huang D.W., Lempicki R.A., Baseler M.W., et al. Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. J.Immunol. 2011, 186:4541-4545.
154. Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., Abbas A.R., Modrusan Z., Ghilardi N., de Sauvage F.J., Ouyang W. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 2008, 14:282-289.
155. Zhou Z., Hamming O.J., Ank N., Paludan S.R., Nielsen A.L., Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J.Virol. 2007, 81:7749-7758.
156. Zhou P., Cowled C., Marsh G.A., Shi Z., Wang L.F., Baker M.L. Type III IFN receptor expression and functional characterisation in the pteropid bat, Pteropus alecto. PLoS ONE 2011, 6:e25385.
157. Zhou P., Cowled C., Todd S., Crameri G., Virtue E.R., Marsh G.A., Klein R., Shi Z., Wang L.F., Baker M.L. Type III IFNs in pteropid bats: differential expression patterns provide evidence for distinct roles in antiviral immunity. J.Immunol. 2011, 186:3138-3147.